Fertility Tech Investors
CapLink currently tracks 5 verified investors focused on Fertility Tech — a small but growing slice of the global funding landscape.
The mix is led by PE/Buy-Out and VC. Deal coverage spans Seed through PE/Buy-out, with the largest concentration at PE/Buy-out.
Investor headquarters cluster in United States, Canada, Mexico, Costa Rica and Panama, with activity across 132 countries in total. Ticket sizes range from roughly $1.0M to $200M, covering early angel cheques through to growth-stage rounds.
Use the pre-filtered database below to explore every Fertility Tech investor on CapLink, or sign up to unlock contact details, ticket sizes and detailed investment criteria.
Fertility Tech investor database
5 investors matched for Fertility Tech. Sign up to unlock contact details and full profiles.
| Investor |
|---|
 Recharge Capital Recharge Capital, LLC is a venture capital firm specializing in incubation, early-stage, seed/startup, late-stage investments. The firm prefers to invest through growth capital transactions. The firm seeks to invest in fintech focusing on traditional and Web3, synthetic biology, digital asset infrastructure, fintech infrastructure, women's healthcare focusing on international fertility tourism, menstrual wellness, and women’s disease prevention and semiconductor technology sectors. It prefers investment in Southeast Asia, LatAm, Europe, and the Middle East. Recharge Capital, LLC was founded in 2016 is based in New York, New York with additional offices in Singapore, Singapore; Los Angeles, California and Hong Kong and Beijing, China. |
 Sandkey Capital, LLC Sandkey Capital, LLC is a private equity firm specializing in direct and fund of fund investments. Within direct investments it invests in lower, core, and upper middle market, buy and build, Recapitalizations, restructurings, Buyout, Growth Capital as well as add-on acquisitions. In case of lower middle market the firm also seeks businesses in transition including family/founder & entrepreneur-led businesses, corporate carve-outs, Underperformers, complex & special situations that have growth challenges, succession issues, managing rapid growth, and are in need of a sophisticated partner; corporate carve-outs of non-core, under-invested, and under-managed business; underperformers that are under-managed, under-invested, lagging peer group performance; and turnarounds for companies in operational distress and cyclical/out of favor industries. Within fund of fund investments, it specializes in Private equity funds. The firm typically invests in insurance services, Retailing, Consumer Services, Pharmaceuticals, Biotechnology, life Sciences, insurance distribution, consumer products, retail, industrial manufacturing and services sectors sector. Within these sectors it focuses on specialty medical device manufacturers, product manufacturers, and distributors; consumer product sector focusing on general consumer, food and beverage, such as sweet and salty snacks, producer of shelf-stable food products, pet food, refrigerated dips, desserts, and specialty products, food distribution, frozen foods supplier focused on ready meals, fish/seafood and vegetables, Seafood company in frozen & chilled markets, processing, aquaculture, wild catch, poultry processor, pork processor, clean label / natural ingredients, leading independent coffee roasting business,, food & beverage packaging, beauty & personal products, household care products, Personal Care, Household Care, Pet Products & Services, Franchisee, Franchisor, Multi-Unit Businesses, packaged goods, home furnishings, apparel; retail sector focusing on general retail, athletic retail, home furnishings, apparel, footwear and Industrial manufacturing & services sector focusing on general manufacturing & distribution, automotive & transportation, building products, chemicals, aerospace & defense, paper and packaging, PCBA / EMS; business services focusing on technology and technology-enabled services, logistics, business process outsourcing, education and training, marketing & information services, home services. In the healthcare sector the firm seeks add-on initiatives in pharma contract development and manufacturing organizations and Nuclear Medicine Solutions Provider with a focus on contract manufacturing, API producers, contract drug development, clinical trial services, and logistics, Pharmaceutical CDMO, cancer and coronary hospital, Mobile surgery units, Dental clinics, Veterinary clinics, Fertility treatment, Pharmacies, Outpatient clinics, Mental illness care, Health insurance, Physical rehab, Pharmaceutical distribution, Pharmaceutical packaging, Community Healthcare Services. In case of core and upper middle market, the firm seeks to invest in consumer goods, healthcare, and essential services. In case of lower middle market, the firm seeks to invest in consumer, retail, manufacturing and business services. For upper middle market companies, the firm seeks to invest in North America. The firm prefers to invest between $10 million and $200 million of equity investment in companies having, EBITDA between $3 million and $35 million, revenue of $10 million and $300 million and enterprise value between $20 million to $600 million. The firm prefers to make control and minority equity investments. It prefers to hold companies for three to seven years in healthcare sector. The firm makes personal capital and balance sheet investments. Sandkey Capital, LLC was founded in 2016 and is based in Florida. |
 Bram Capital Partners LLC. Bram Capital Partners LLC. is a private equity firm specializing in buyout, industry consolidation, carve-outs, recapitalization, and turnaround transactions of small to lower middle-market businesses. The firm targets small-cap under performing, operationally distressed or financially troubled companies and non-core divisions of larger conglomerates. It focuses on capital, asset, operationally challenged businesses, and/or labor-intensive businesses in sustainable industries with a primary interest in manufacturing; assembly, distribution, consumer, industrials and fabrication; wholesale trade; business services; retail trade; health care; transportation; and warehousing. It does not invest in industries with short product life cycles. The firm also seeks to invest in special situations like manufacturing plants, service business attached to OEM, and distressed assets. Within the manufacturing, assembly, distribution, and fabrication sectors it focuses on transportation equipment; lumber and building products; finished textile products; chemicals and pharmaceuticals; food and beverage manufacturers; stone, clay, glass and concrete; beverages and tobacco products; petroleum and coal products; nonmetallic mineral products; clothing and clothing accessories; distributors, packaging manufacturers; and other manufacturing sectors. Within the wholesale trade sector, the firm seeks to invest in industrial supplies, marine dealers and equipment, packaging supplies, construction equipment dealers, agricultural equipment dealer, and scrap metal dealer sectors. Within the business services sector, it focuses on equipment rental and maintenance, waste management and remediation services, industrial laundry, restaurant services, collection agencies, and commercial refrigeration services sectors. Within the retail trade sector, the firm prefers to invest in the home medical equipment and building materials, hardware, garden sectors, and event supplies including sales and rentals. Within the healthcare sectors, it focuses on home healthcare services, radiology centers, vision veterinary, physical therapy, dermatology, urgent care, healthcare IT, telehealth, fertility and dental practices sectors. Within the transportation and warehousing sectors, the firm seeks to invest in the rail transportation, trucking companies, moving companies, towing companies, water transportation, logistic services, and bus companies sectors. It prefers to invest in privately held or public North American companies or non-core or under performing divisions of diversified corporations. The firm typically invests between $1 million and $10 million in companies with highly levered businesses or stressed capital structure, having revenues between $20 million and $150 million, enterprise values between $3 million and $40 million, and a maximum EBITDA of $6 million or cash flow less than 10% of revenues. Bram Capital Partners LLC. was co-founded in 2007 and is based in Boston, Massachusetts with an additional office in New York, New York. |
 Lead Capital Partners, LLC Lead Capital Partners, LLC is a private equity firm specializing in investments in owner recapitalizations, management buy outs, growth capital, family successions, and corporate divestitures. It typically invests in lower middle market stages. It seeks to invest in Healthcare Services including clinical and non-clinical staffing, clinical research organizations, credentialing and provider services, employee health and wellness, governance, risk, compliance, IT support or optimization, laboratory services, payer and provider consulting, revenue cycle management, specialty pharmacy and value-added distribution; Healthcare IT including continuing education or training, cyber security, data analytics, practice management, revenue cycle management, telemedicine, utilization or population management and vendor management system and Provider Based Platforms including adult & adolescent behavioral health, autism treatment services, dental, dermatology, home health or hospice, occupational and workplace medicine, ophthalmology, physical therapy, primary care, substance use disorder, urgent care, and women's health or fertility; and other specialty ppms; business services; consumer product; marketing services; hospitality services; infrastructure; niche manufacturing; and industrial services. It invests in companies based in Southeast, Southwest, Mid Atlantic, Midwest, Northeast and Continental United States. The firm seeks to invest in companies with enterprise value between $5 million and $50 million, revenue between $10 million and $75 million and EBITDA between $2 million and $7 million. It prefers to invest in companies that tend to have few fixed assets, limited capital expenditure requirements, recurring revenues, strong free cash flow, sustainable profit margins, and identified prospects for growth. It seeks to acquire majority stakes interests in companies and a Board seat on its portfolio companies. It is a multifamily sponsored firm. Lead Capital Partners, LLC was founded in 2011 and is based in Nashville, Tennessee. |
 Shenzhen Qianhai BangQin Investment Co., Ltd. Shenzhen Qianhai BangQin Investment Co., Ltd. is a venture capital firm specializing in start-ups investment. The firm typically invests in artificial intelligence, military-civilian integration, life and health sector, including biomedical and fertility-related fields. It prefers to invest in China. Shenzhen Qianhai BangQin Investment Co., Ltd. was founded in 2016 and is based in Shenzhen, China. |
Understanding Fertility Tech investors
What are Fertility Tech investors, and what do they look for?
Fertility businesses sit between healthcare and consumer, and which side you fall on determines how investors assess you. Clinical services and diagnostics face regulatory requirements, clinical evidence expectations and reimbursement questions. Consumer tracking, education and support products face acquisition costs and retention questions with no regulatory burden and considerably less pricing power. Companies that blur the two tend to inherit the difficulties of both. Where reimbursement applies, investors examine it carefully, because European coverage for fertility treatment varies enormously between countries in how many cycles are funded, at what age and under what conditions. A business model that works where treatment is publicly funded may not work across the border. Clinical outcomes are the third pillar for anything touching treatment. Success rates are the metric patients and clinics compare on, and they are heavily influenced by patient selection, so investors will ask how outcomes were measured and against which population. Claims that do not adjust for the patients treated are treated sceptically.
Why Fertility Tech is attracting investor interest
People are starting families later, and the biology has not adjusted. Average age at first birth has risen across essentially every European country, which increases the proportion of people who encounter difficulty conceiving and expands the addressable population for treatment, diagnostics and preservation services independently of any technology change. Employer benefits opened a second funding channel. Companies competing for staff have begun covering fertility treatment and preservation, particularly in sectors with young professional workforces, which creates a payer that is neither the patient nor the state and buys on a corporate procurement cycle. Clinical capacity has not kept pace with demand in most European systems, producing waiting times that push patients towards private provision and creating room for companies that improve throughput, streamline diagnostics or extend care beyond the clinic. Investors also note that this has been a chronically underfunded category relative to the number of people affected, which several funds have identified explicitly as a mispricing rather than a reflection of market size.
Which funding stages Fertility Tech investors are active at
Funding here follows the healthcare or consumer split more than the stage. Seed rounds back clinical services, diagnostics or consumer products with early users. For clinical businesses, investors weigh medical credibility on the team heavily; for consumer, they weigh retention and acquisition economics. Series A requires demonstrated demand and, for clinical models, evidence of outcomes and a reimbursement or payer position. Consumer fertility products face the standard difficulty that engagement is intense during a defined period and then ends, which makes lifetime value harder to build than in other health categories. Series B funds geographic expansion, which in Europe means confronting different regulation, funding regimes and cultural attitudes country by country. Investors examine how much of the model transfers. Clinic networks and service providers attract different capital again, closer to healthcare services investing and private equity than to venture, since the economics are operational and the growth comes from adding capacity. Strategic acquirers include laboratory groups, clinic chains and womens health companies.
Types of investors active in Fertility Tech
Investors focused on a category that has been chronically underfunded, with genuine understanding of clinical pathways and patient behaviour. They are realistic about the episodic nature of fertility engagement and about which models sustain revenue beyond a single treatment journey.
Funds backing regulated care delivery, evaluating outcomes evidence, clinical governance and reimbursement position. They are the right audience for anything touching diagnosis or treatment and apply healthcare rather than consumer standards.
Corporate investors from fertility clinic networks and diagnostic laboratories. They provide clinical settings for validation, patient access and distribution, and they are the most likely acquirers of technology serving treatment.
Capital focused on the workplace benefits channel, which has become a meaningful payer for fertility services. They evaluate against employer procurement and retention outcomes rather than consumer acquisition.
Funds backing tracking, education and support products with no clinical claim. They apply consumer subscription economics and are the wrong audience for regulated services, which is a distinction worth respecting when building a target list.
Ready to reach Fertility Tech investors?
Create a free CapLink account to unlock full investor profiles, contact details, ticket sizes and intelligent matching.